Type 2 Diabetes Clinical Trial
Official title:
Effectiveness of Share Care Diabetes Management in Patients With Type 2 Diabetes
This is a prospective, randomization, parallel, controlled study, which conducted to evaluate the effectiveness and related influencing factors of the Shared Care multidisciplinary diabetes care model. Patients with T2DM involved in the Shared Care model pay regularly quarterly visit to a multidisciplinary team led by physician at outpatient clinic, and receive remote and systematic management and education online after going home. After at least one year follow-up, evaluate the glycemic achieving rate (HbA1c<7%), the diabetes self-management behavior change and the effect of online diabetes self-management support for patients of the Shared Care multidisciplinary diabetes care model.
Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial
risk-reduction strategies beyond glycemic control. At present, about 114 million diabetics
and 11.6% incidence rate of diabetes in China have produced huge chronic disease management
pressure and created great challenges for China's limited medical resources. (1-5).
Meanwhile, with population aging and increasing prevalence of obesity in China, the number of
patients with diabetes mellitus, diabetes-related complications and related mortality are
expected to further increase, which also indicates greater healthcare expenditure and
socioeconomic burden. A multi-center, cross-sectional survey of outpatients conducted in 606
hospitals across China showed that the majority of patients with type 2 diabetes did not
achieve the goal of HbA1c <7.0% (6). There are varieties of problems including inadequate
patient education, inability to track the out-of-hospital situation of diabetes, and lack of
effective patient follow-up and education between each visits (1-5). Many researches have
proved that comprehensive diabetes management education can significantly improve the quality
of life of patients, decrease the incidence and mortality of diabetes complications, and
relieve the government's medical economic burden (7). Besides, A number of studies have shown
that the early detection and comprehensive management of diabetes can prevent the occurrence
of a variety of complications and decrease the disability rate and premature death rate of
diabetes. Therefore, how to improve the current situation of diabetes control in China is
very important and a real problem in front of every doctor, patient and health institution.
According to the diabetes management guidelines published by American Diabetes
Association(ADA) and the National Institutes of Health(NIH), continuous follow-up of
patients, diabetes self-management education and support (DSME/S) combined with
multidisciplinary team comprehensive management can be abled to achieve better management
results, and it is also a more comprehensive and cost-effective way to manage diabetic
patients (8-12). In order to support health professionals to improve medical efficiency and
promote patients develop healthy lifestyle, Shared Care diabetes management model established
and believe that it will provide a sustained and effective solution for improving the
effectiveness of comprehensive management for patients and reducing the burden of national
chronic disease management.
The Shared Care aims to provide patients with a continuous management model of
omni-directional and lifelong care management, and to strengthen diabetes self-management
education and supports (DSME/S), achieve better health outcomes and delay incidence and
mortality of diabetic complications. The model consisted of a medical team that includes
dietitians, diabetes educators, nurses and physical therapist led by physician, and provides
comprehensive disease and health management for patients with diabetes through outpatient
consultation and out-of-hospital online continuous management. The management strategy is
adjusted and individualized based on patients' habit and situation. Compared with traditional
diabetes outpatient settings, patients of Shared Care return to the hospital for regular
follow-up every three months since the initial visit after the informed consent. For each
follow-up, a comprehensive management plan is made by a multidisciplinary team, including
doctor consultation, diabetes management, foot evaluation, fundus assessment, insulin
injection assessment, exercise evaluation and guidance, etc. The patients download the Shared
Care mobile application during the outpatient service and connect with the smart-glucometer
BG1 to upload blood glucose dairy, blood pressure diary and food log in real time.
With patient's informed consent, Patient-related vital signs (such as height, weight, body
mass index, blood pressure, waist, hips), laboratory indicators (including glycated
hemoglobin, low-density lipoprotein, total cholesterol, triglycerides, kidney indicators such
as urine microalbumin and creatinine Ratio, glomerular filtration rate), blood glucose
records, online learning frequency and other data will be uniformly recorded and
comprehensively analyzed.
All out-of-hospital online diabetes educators are qualified as registered nurses. Before the
start of the study, the nurses should uniformly receive training and examination related to
diabetes education in the Department of Endocrinology of Chaoyang Hospital. The main contents
of online education include personalized assessment and suggestions on diet, hyperglycemia
and hypoglycemia events, drug use and insulin preservation as directed by doctors, and on
blood glucose monitoring and reminders for revisit every three months, etc. In case of
special circumstances or prescription adjustment, online diabetes educators should follow the
training process to summarize the patient's condition with the doctor on the same day or
during the weekly regular outpatient clinic, or arrange additional subsequent visit of the
patient, all online consultation process is carried out under the supervision of the doctor
(the diabetes educator spends about 5 minutes a week to discuss the condition of special
patients with the doctor according to the actual situation). The model enables both patients
and medical teams to carry out real-time data sharing, intelligent analysis and remote
monitoring, thus significantly improving management efficiency and releasing medical
resources.
A series of preliminary studies had been conducted in Chaoyang Hospital since January 2018.
mean age of patients enrolled was 54.69 ± 11.14 years; the duration of diabetes was more than
7.8 ±7.0 years, and more than 70% were complicated with hypertension and / or dyslipidemia.
The baseline glycemic achieving rate of patients with a duration more than 10 years was less
than 35%. After participated in the Shared Care management model, glycemic achieving rate of
patients with diabetic was more than 75%. Compared with the baseline HbA1c 7.4±1.5%, patients
HbA1c in the latest follow-up was 6.6 ±1.0%, with the average decreased of 0.8 ±1.6% (P
<0.05). The 3B achieving rate (HbA1c <7%, LDL-C < 2.6mmol/L, BP <130/80mmHg) of patients
under the management of Shared Care Model was 21.84%. The baseline urinary microalbuminuria /
creatinine (UACR) 35.8mg/g was not significantly increased compared with the last follow-up
of 32.1mg/g (P>0.10). The daily cost of hypoglycemic medicine was significantly reduced in
patients with the duration of diabetes less than 2 years or 15 years or more (medicine daily
cost of the baseline and the latest follow-up was 3.5 RMB per day and 2.3 RMB per day
respectively in patients with the duration of diabetes less than 2 years (P<0.05); medicine
daily cost of the baseline and the latest follow-up was 10.4 RMB per day and 9.5 RMB per day
respectively in patients with the duration of diabetes of 15 years or more (P<0.05)), but
there was no significant increase in patients with other durations of diabetes.
The study evaluated and explored the effect of patient management and related factors under
the Share Care management model aims to provide a clear evidence for the choice of new
diagnosis and treatment strategies for patients with diabetes.
All patients enrolled in the study need to go through screening, initial visit, revisit,
half-year visit and annual visit. The following is an overview of the research design.
Screening:
210 patients with type 2 diabetes who met the criteria were enrolled. All patients with
informed consent will undergo basic interviews, vital sign measurements and related
biochemical tests. During the screening phase, the following variables will be collected:
age, sex, smoking status (current smokers, former smokers, non-smokers), duration of
diabetes, duration of dyslipidemia, concomitant diseases and medication, etc. Besides, vital
signs, 12-lead electrocardiogram, regular blood test and glycated hemoglobin (HbA1c), the
patient's blood lipid spectrum includes total cholesterol (TC), triglyceride (TG), High
density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C),
albumin-to-creatinine ratio(ACR) and safety laboratory measurements (creatine kinase, SCr,
BUN, UA, ALT, AST) also will be collected. The designated researcher will conduct a serum
pregnancy test on all fertile women. The body mass index ((BMI)) is calculated by dividing
weight by the square of height (kg / m2). After fasting overnight for 8 to 12 hours, the
blood samples were collected before breakfast the next day. EGFR will be calculated using a
Modification of diet in renal disease (MDRD).
Initial visit:
- Check the inclusion / exclusion criteria to confirm whether subjects are eligible to
participate in the study. After confirming, the subjects will be randomly divided into
the shared care group or the traditional therapy group according to the random number
table.
- Basic vital signs: including height, weight, waist, hips, blood pressure, etc.
- Collection of metabolic indicators: HbA1c, ACR, blood biochemistry, etc.
- The number and days of emergency visits or hospitalizations due to diabetes-related
factors (diabetic ketoacidosis, diabetic hyperosmotic coma, severe hypoglycemia) in the
past three months before joining the study
- Filling in and recording the related behavior scale (summary of diabetes self-care
activities (SDSCA), chinese diabetes management self-efficacy scale(C-DMSES), adjusted
diabetes-specific quality of life scale (A-DQOL), morisky drug compliance scale and
depression-anxiety-stress scale (DASS-21)).
- Insulin evaluation (including rotation of patients' insulin injection site, each change
of needle, skin condition, preservation of insulin and correct use of insulin pen, etc.)
- Fundus evaluation.
- Foot evaluation.
- Health education.
- Daily medicine cost of patients
Revisit (every three months):
- Basic vital signs: including height, weight, waist, hips, blood pressure, etc.
- Collection of metabolic indicators: HbA1c, ACR, blood biochemistry, etc.
- The number and days of emergency visits or hospitalizations in the last three months (or
since the last visit) due to diabetes-related factors (diabetic ketoacidosis, diabetic
hyperosmotic coma, severe hypoglycemia)
- Daily medicine cost of patients half-year visit (every 6 months from the initial visit)
needs to be added on the basis of the index of revisit.
- Basic vital signs: including height, weight, waist, hips, blood pressure, etc.
- Collection of metabolic indicators: HbA1c, ACR, blood biochemistry, etc.
- The number and days of emergency visits or hospitalizations in the last three months (or
since the last visit) due to diabetes-related factors (diabetic ketoacidosis, diabetic
hyperosmotic coma, severe hypoglycemia).
- Daily medicine cost of patients.
- Insulin evaluation.
Annual visit (every 12 months from the initial visit) in addition to all the indicators of
revisit, there is also an increase:
- Filling in and recording the related behavior scale (summary of diabetes self-care
activities (SDSCA), chinese diabetes management self-efficacy scale(C-DMSES), adjusted
diabetes-specific quality of life scale (A-DQOL), morisky drug compliance scale and
depression-anxiety-stress scale (DASS-21)).
- Insulin evaluation (including rotation of patients' insulin injection site, each change
of needle, skin condition, preservation of insulin and correct use of insulin pen, etc.)
- Fundus evaluation.
- Foot evaluation.
- Insulin evaluation.
After being included in the study, patients were randomly divided into two groups: shared
care group (experimental group) or traditional therapy group (control group). The total
observation period for each patient was 1 year. Follow-up was carried out every 3 months. At
each visit, the patient's basic condition, various vital signs and metabolic indicators,
daily medicine cost of patients, and the number and days of emergency visits or
hospitalizations in the last three months (or since the last visit) due to diabetes-related
factors (diabetic ketoacidosis, diabetic hyperosmotic coma, severe hypoglycemia) will be
collected.
Patients can download the Shared Care mobile application and connect with the
smart-glucometer BG1 to upload blood glucose dairy in real time during the clinic. With
patient's informed consent, the patient's follow-up data, laboratory indicators, etc. are
uniformly collected and recorded for analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |